Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Dow
Mallinckrodt
Colorcon
Medtronic

Last Updated: December 5, 2019

DrugPatentWatch Database Preview

Vincristine sulfate - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic sources for vincristine sulfate and what is the scope of patent protection?

Vincristine sulfate is the generic ingredient in six branded drugs marketed by Acrotech, Lilly, Teva Parenteral, Bristol Myers Squibb, Abic, Abraxis Pharm, Fresenius Kabi Usa, Hospira, and Teva Pharms Usa, and is included in thirteen NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Vincristine sulfate has forty-six patent family members in sixteen countries.

There are thirteen drug master file entries for vincristine sulfate. Four suppliers are listed for this compound.

Recent Clinical Trials for vincristine sulfate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
AIDS Malignancy ConsortiumEarly Phase 1
National Cancer Institute (NCI)Early Phase 1
University of WashingtonPhase 1

See all vincristine sulfate clinical trials

Recent Litigation for vincristine sulfate

Identify potential future generic entrants

District Court Litigation
Case NameDate
Pharmacia & Upjohn v. Sicor Inc.2004-07-08

See all vincristine sulfate litigation

Pharmacology for vincristine sulfate
Drug ClassVinca Alkaloid
Medical Subject Heading (MeSH) Categories for vincristine sulfate
Synonyms for vincristine sulfate
068V782
2068-78-2
22-oxovincaleukoblastine sulfate
AB0105888
AB48730
AC1L6O8Q
AI3-52944
AK206276
AKOS015895862
Alkaloid extracted from Vinca rosea Linn
AQTQHPDCURKLKT-JKDPCDLQSA-N
C13974
C46H56N4O10.H2O4S
CCRIS 2583
CHEBI:79401
CHEMBL501867
D02197
DTXSID8044331
EINECS 218-190-0
I06-1238
KB-276095
Kyocristine
l)-6-formyl-5-hydroxy-8-methoxy-3a,3a1,4,5,5a,6,11,12-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate sulfate
LCR
Leurocristine
Leurocristine sulfate
Leurocristine sulfate (1:1)
Leurocristine sulfate (1:1) (salt)
Leurocristine, sulfate
Leurocristine, sulfate (1:1) (salt)
Lilly 37231
LS-87932
Marqibo (TN)
MLS002702994
MolPort-006-069-042
NSC 67574
NSC-67574
NSC67574
Oncovin
Oncovin (Lilly)
Oncovin (TN)
Onkovin
SCHEMBL3710
VCR
VCR sulfate
Vincaleukoblastine, 22-oxo-, sulfate (1:1) (salt)
Vincasar (TN)
Vincasar PFS
Vincrex
Vincrex (TN)
Vincristine sulfate (JP17/USP)
Vincristine sulfate [USAN:JAN]
vincristine sulfate liposomes
Vincristine Sulfate PFS
Vincristine sulphate
Vincristine, sulfate
Vincristinsulfat [German]
Vincrisul
Z-3315
Paragraph IV (Patent) Challenges for VINCRISTINE SULFATE
Tradename Dosage Ingredient NDA Submissiondate
ONCOVIN INJECTABLE;INJECTION vincristine sulfate 014103

US Patents and Regulatory Information for vincristine sulfate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abic VINCRISTINE SULFATE vincristine sulfate INJECTABLE;INJECTION 070873-001 Feb 19, 1987 DISCN No No   Start Trial   Start Trial   Start Trial
Abraxis Pharm VINCRISTINE SULFATE vincristine sulfate INJECTABLE;INJECTION 070411-001 Sep 10, 1986 DISCN No No   Start Trial   Start Trial   Start Trial
Lilly ONCOVIN vincristine sulfate INJECTABLE;INJECTION 014103-003 Mar 7, 1984 DISCN No No   Start Trial   Start Trial   Start Trial
Acrotech MARQIBO KIT vincristine sulfate INJECTABLE, LIPOSOMAL;INTRAVENOUS 202497-001 Aug 9, 2012 RX Yes Yes   Start Trial   Start Trial   Start Trial
Hospira VINCRISTINE SULFATE vincristine sulfate INJECTABLE;INJECTION 071559-001 Apr 11, 1988 DISCN No No   Start Trial   Start Trial   Start Trial
Acrotech MARQIBO KIT vincristine sulfate INJECTABLE, LIPOSOMAL;INTRAVENOUS 202497-001 Aug 9, 2012 RX Yes Yes   Start Trial   Start Trial   Start Trial
Hospira VINCRISTINE SULFATE PFS vincristine sulfate INJECTABLE;INJECTION 071484-001 Apr 19, 1988 AP RX No Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for vincristine sulfate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Acrotech MARQIBO KIT vincristine sulfate INJECTABLE, LIPOSOMAL;INTRAVENOUS 202497-001 Aug 9, 2012   Start Trial   Start Trial
Lilly ONCOVIN vincristine sulfate INJECTABLE;INJECTION 014103-003 Mar 7, 1984   Start Trial   Start Trial
Acrotech MARQIBO KIT vincristine sulfate INJECTABLE, LIPOSOMAL;INTRAVENOUS 202497-001 Aug 9, 2012   Start Trial   Start Trial
Acrotech MARQIBO KIT vincristine sulfate INJECTABLE, LIPOSOMAL;INTRAVENOUS 202497-001 Aug 9, 2012   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
Mallinckrodt
Dow
Medtronic
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.